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HumanizationDENV1-E106 is a monoclonal antibody (MAb) with strong neutralizing activity against all ﬁve DENV-1 geno-
types and therapeutic activity in mice. Here, we evaluated the potential for DENV-1 to escape neutralization
by DENV1-E106. A single mutation in domain III of the envelope protein (T329A) emerged, which conferred
resistance to DENV1-E106. However, the T329A variant virus had differing phenotypes in vitro and in vivo
with attenuation in cell culture yet increased infectivity in Aedes aegypti mosquitoes. Mice infected with
this T329A variant still were protected against lethal infection by DENV1-E106 even though much of the neu-
tralizing activity was lost. This study reveals the complex dynamics of neutralization escape of an inhibitory
MAb against DENV, and suggests that evaluation of therapeutic MAbs requires detailed investigation in rele-
vant hosts.
© 2012 Elsevier Inc. All rights reserved.Introduction
Dengue virus (DENV) infection after mosquito inoculation causes
clinical disease ranging from a self-limiting febrile illness (Dengue
Fever, DF) to a life threatening hemorrhagic and capillary leak syndrome
(Dengue Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS)).
DENV is the most prevalent mosquito-transmitted viral disease and
causes an estimated 50 to 100 million infections and 250,000 cases of
DHF/DSS per year worldwide, with 2.5 billion people at risk (Halstead,
1988; Monath, 1994). Globally, there is signiﬁcant diversity among
DENV strains, including four serotypes (DENV-1, DENV-2, DENV-3, and
DENV-4) that differ at the amino acid level by 25 to 40% andmultiple ge-
notypes within a serotype that vary by up to ~6% (Holmes and Twiddy,, Molecular Microbiology and
l of Medicine, 660 South Euclid
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rights reserved.2003; Rico-Hesse, 1990). At present, no approved antiviral treatment
or vaccine is available, and therapy remains supportive.
The potential of passive immunotherapy for ﬂavivirus infection has
prompted the development and evaluation of several neutralizing
human or humanized monoclonal antibodies (MAbs) against West
Nile, Japanese encephalitis, and Dengue viruses (Balsitis et al., 2009;
Beltramello et al., 2010; Goncalvez et al., 2008; Gould et al., 2005;
Schieffelin et al., 2010; Sultana et al., 2009; Throsby et al., 2006). Re-
cently, we described a panel of inhibitory DENV-1-speciﬁc MAbs, of
which only four were highly protective in an IFNαβR−/−×IFNγR−/−
AG129 mouse model of DENV-1 infection (Shrestha et al., 2010).
One of these MAbs, DENV1-E106, strongly neutralized all ﬁve DENV-
1 genotypes in cell culture and was active therapeutically even when
administered as a single dose four days after infection in mice. Map-
ping studies by yeast display suggested that DENV1-E106 recognizes
a composite epitope on the A-strand and lateral ridge of domain III
(DIII) of the envelope (E) protein. As ﬂaviviruses have an error-
prone RNA polymerase, replication can result in rapid viral evolution.
Thus, the potential for emergence of resistant variants is a signiﬁcant
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which humans play a requisite role in the natural transmission cycle.
In this study, we selected for neutralization escape mutations
of DENV1-E106. A single mutation in DIII of the E proteinFig. 1. Phenotype of the DENV-1 T329A neutralization escape variant. A. Neutralization curv
gous West-Pac-74 DENV-1 strain (genotype 4), and the T329A West-Pac-74 DENV-1 strain
pendent experiments performed in duplicate on BHK21-15 cells. B–C. Yield of wild type an
different input MOI in the (B) absence or (C) presence of DENV1-E106. The data are the av
differences that are statistically signiﬁcant. Dashed lines indicate the limit of detection of th
RVP. Genetically engineered DENV-1 RVP displaying the structural proteins of (D) West-Pac
bated with increasing concentrations of DENV1-E106. F. Neutralization curves of DENV1-E1
stitution into an infectious cDNA clone. The data are representative of two independent expe
RVP (strain West-Pac-74) with single mutations (G) K90R in prM or (H) V83L in E or both
E106 and analyzed by ﬂow cytometry. For D, E, and G–I, representative data of experimen
of the mean of duplicate infections.(T329A) was identiﬁed that conferred resistance to DENV1-E106.
This T329A variant virus had differing phenotypes in vitro and in
vivo with attenuation in cell culture yet paradoxically enhanced
infectivity in mosquitoes. Moreover, mice infected with thises with DENV1-E106 and the parent 16007 DENV-1 strain (genotype 2), the heterolo-
derived directly from passage in cell culture. The data are representative of three inde-
d T329A West-Pac-74 DENV-1 from supernatants of BHK21-15 cells after infection at
erage of three independent experiments performed in duplicate and asterisks indicate
e assay. D–E. Conﬁrmation of resistant phenotype with wild type and mutant DENV-1
-74 or (E) 16007 with or without a single amino acid substitution (T329A) were incu-
06 with wild type or T329A West-Pac-74 DENV-1 strains derived by site-directed sub-
riments performed in duplicate on BHK21-15 cells. G–I. Genetically engineered DENV-1
mutations (I) K90R+V83L were incubated with increasing concentrations of DENV1-
ts performed on Raji-DCSIGNR cells is shown. Error bars represent the standard error
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DENV1-E106. This study reveals the complex dynamics of escape
of a strongly neutralizing MAb against DENV in mice and
mosquitoes.
Results
Selection of a neutralization escape variant in cell culture
DENV1-E106 is an inhibitory sub-complex speciﬁc MAb that neu-
tralized infection of strains corresponding to all ﬁve DENV-1 geno-
types and improved clinical outcome in mice when administered as
a single dose four days after infection with the West-Pac-74 (geno-
type 4) strain of DENV-1 (Shrestha et al., 2010). Given its broad-
spectrum antiviral activity against all DENV-1 genotypes and possible
therapeutic potential, we questioned whether resistance would occur
under selective pressure during the course of treatment. Prior map-
ping studies identiﬁed putative recognition sites for DENV1-E106
MAb in the A-strand (K310) and lateral ridge of DIII (G328, T329,
D330, P325, K361, E362, P364, and K385), as mutations in these resi-
dues reduced binding to DIII when expressed on the surface of yeast
(Shrestha et al., 2010). To begin to identify key functional residues
on DIII that engaged DENV1-E106, we selected for neutralization es-
cape mutants in cell culture. We used DENV-1 West-Pac-74, a geno-
type 4 strain, since it was more resistant (12-fold, Pb0.01, Fig. 1A)
to DENV1-E106 compared to the genotype 2 strain 16007, and thus
might be easier to recover escape variants. After three sequential pas-
sages of DENV-1 strain West-Pac-74 in BHK21-15 cells in the pres-
ence of 10 μg/ml of MAb, a resistant virus emerged that no longer
was efﬁciently neutralized (EC50 of 7860 ng/ml of escape variant ver-
sus 16 ng/ml of wild type, P=0.005, Fig. 1A); nonetheless, as high
concentrations of MAb did inhibit infection, the escape mutant must
still bind DENV1-E106, albeit with markedly reduced afﬁnity.
To determine the mutations that conferred the neutralization es-
cape phenotype, viral RNA sequenceswere obtained from 30 indepen-
dent plaque-puriﬁed escape variants and compared to the wild type
DENV-1 sequence derived from virus propagated in parallel in the ab-
sence of MAb selection. All (30 of 30) escape variants contained only a
single-nucleotide change (T to A) encoding a T329Amutation in the E
protein, as no other changeswere identiﬁed. To understand the signif-
icance of the T329A change, we assessed the growth kinetics of wild
type and escape variant (T329A) viruses in the absence or presence
of 10 μg/ml DENV1-E106 MAb in BHK21-15 cells. Notably, in the ab-
sence of antibody, T329A DENV-1 grew less well as evidenced by a re-
duced percentage of infected cells and lower (up to 70-fold, Pb0.001)Fig. 2. Growth analysis and stability of DENV-1 T329A neutralization escape variant. A–B. Mu
(B) C6/36 cells. Cells were infected at an MOI of 0.01 and supernatants were harvested at 24
dent experiments performed in duplicate and asterisks indicate differences that are statist
DENV-1 infected (C) BHK21-15 or (D) C6/36 cells and used for PRNT analysis to assess stab
dent experiments performed in duplicate on BHK21-15 cells.viral titers at 48 h over a broad range (0.01 to 5) of multiplicities of in-
fection (MOI) (Fig. 1B, and data not shown). However, in the presence
of MAb, while virtually no virus was recovered in the supernatants of
cells infectedwithwild type virus at 48 h, T329A virus was obtained at
several different MOI (Fig. 1C). As additional conﬁrmation, we gener-
ated a T329A mutant virus using two different reverse-genetic strate-
gies. First, DENV-1 RVP (Ansarah-Sobrinho et al., 2008; Dowd et al.,
2011) corresponding to West-Pac-74 or 16007 strains were engi-
neered with or without a single amino acid mutation at T329A, pro-
duced in HEK293T cells, and analyzed for MAb neutralization.
Whereas DENV1-E99 MAb (which maps to residues E309, K310, and
E311 on the A-strand of DIII (Shrestha et al., 2010)) neutralized both
wild-type and T329A RVP equivalently (data not shown), DENV1-
E106 failed to efﬁciently neutralize the T329A mutant in either the
West-Pac-74 or 16007 backgrounds (Figs. 1D and E). As a ﬁnal conﬁr-
mation, we introduced the T329A substitution into an infectious cDNA
clone of DENV-1 West-Pac-74 (Whitehead et al., 2003). As expected,
the EC50 of the fully infectious T329A variant generated by reverse ge-
netics showed similar resistance to DENV1-E106 MAb (Fig. 1F) but
retained sensitivity to neutralization by DENV1-E99 (data not
shown). Overall, our results suggest that while the infectivity of wild
type DENV-1 was strongly inhibited by DENV1-E106 MAb, similar
viral titers were observed for the T329A escape variant in the presence
or absence of antibody. However, the T329A mutant virus still was at-
tenuated in BHK21-15 cells compared to wild type virus.
Stability of T329A DENV-1 variant in cell culture and mosquitoes
To further characterize the attenuated phenotype of the T329A
DENV-1 variant in cell culture, we performed multi-step growth ki-
netics in mammalian (BHK21-15) and insect (C6/36) cells. Notably,
in both cell types a 9 to 26-fold reduction in viral yield compared to
wild type virus was observed after infection over a period of 72 to
96 h (Figs. 2A and B). To assess whether the T329A mutation was sta-
ble in BHK21-15 and C6/36 cells, virus was harvested from the super-
natant of the respective cell types at the end of the time course and
used for PRNT assays with DENV1-E106 MAb. No evidence of func-
tional reversion was observed, as virus harvested from BHK21-15 or
C6/36 cells infected with the T329A variant retained its resistant phe-
notype (Figs. 2C and D). Consistent with this, sequencing of RNA from
virus-containing supernatants at 96 h revealed no reversion at amino
acid position 329 of the E protein (data not shown).
Given the growth defect of T329A DENV-1 in C6/36 Aedes albopic-
tus cells, we assessed its infectivity and stability in Aedes aegyptimos-
quitoes. Initially, we conﬁrmed the presence of DENV-1 RNA in thelti-step growth curves of wild type or T329A West-Pac-74 DENV-1 in (A) BHK21-15 or
-hour intervals for titration by plaque assay. The data are the average of three indepen-
ically signiﬁcant. C–D. Supernatants were harvested at 96 h from wild type or T329A
ility of the escape mutation in cell culture. The data are representative of two indepen-
Table 1
Infection and reversion of DENV-1 T329A in Aedes aegypti.
0 to 1 h post infection 14 days post infection 14 days post infection
Virus Number positive (%) Number infected (%) Number revertants (%)
T329A 10/10 (100) 15/69 (22) 1/15 (7)
Wild type 10/10 (100) 0/47 (0) ND
P-value NS 0.0003 ND
Aedes aegypti mosquitoes were fed orally wild type (3.1×106 PFU/ml) or T329A (2.6×106 PFU/ml) DENV-1 in a 1:1 blood to virus ratio. Engorged mosquitoes were harvested im-
mediately (within 1 h) after feeding and screened for presence of DENV RNA or held for a 14-day extrinsic incubation period, after which bodies were harvested for viral RNA se-
quencing as described in the Materials and methods. The results are pooled from independent experiments, and the proportions infected were compared by Fisher's exact test. ND
indicates not determined, as mosquitoes were not infected with the wild type parent DENV-1 West-Pac-74 strain under these conditions. NS indicates no signiﬁcant difference.
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T329A DENV-1 (West-Pac-74 strain) by harvesting at mosquitoes at
1 h after feeding, homogenizing tissues, and analyzing viral RNA by
RT-PCR; notably, no difference in initial infection with wild type or
T329A DENV-1 was observed (Table 1, and data not shown). Remark-
ably, the T329A virus showed greater infectivity (22% for T329A and
0% for wild-type) of mosquitoes after a 14-day extrinsic incubation
period. Sequencing of viral RNA recovered from the whole body of
infected mosquitoes at 14 days post-infection revealed a low (7%)
rate of reversion to wild type virus. Thus, the T329A DENV-1 neutral-
ization escape variant efﬁciently infected the relevant arthropod vec-
tor and did not rapidly revert to the wild type sequence during a
typical (14 day) period of replication in mosquitoes.
Phenotype of T329A DENV-1 in mice
Given that the growth defect of T329A DENV-1 in C6/36 cells did
not correlate with the phenotype in mosquitoes, we hypothesized
that although it was attenuated in BHK21-15 cells, it nonetheless
might still retain virulence in mice; this would suggest that replica-
tion dynamics in some tissue culture cell lines might not reliably pre-
dict phenotypes in animals. To test this, we performed a dose–
response analysis using a stringent intracranial challenge model of
DENV-1 West-Pac-74 in AG129 mice; this model was used because
previously we had observed a dose-dependent change in the mean
survival time of infected mice (Shrestha et al., 2010). Somewhat sur-
prisingly, no difference in overall survival rate or average survival
time was detected between wild type and T329A DENV-1 (West-
Pac-74 strain) after intracranial infection with 101, 102, or 103 PFU
of virus (Figs. 3A, B, and C, P>0.5). Because the intracranial challenge
route bypasses infectivity requirements in peripheral organs, we also
tested for attenuation after intraperitoneal challenge. Using a higherFig. 3. Phenotype of T329A DENV-1 in AG129 mice. A–C. AG129 mice were infected via an in
DENV-1 and followed for survival. The number of animals for each dose ranged from 5 to 6 p
pre-treated with 500 μg of DENV1-E106 prior to infection with wild type or T329A West-Pac
Statistically signiﬁcant differences are described in the text.105 PFU dose, which is required to achieve 100% lethality of the par-
ent DENV-1 West-Pac-74 strain over the course of 3 to 5 weeks
(Shrestha et al., 2010), we now observed mild attenuation of T329A
DENV-1 (Fig. 3D) as reﬂected by a decreased lethality rate (77% ver-
sus 100%, Pb0.02) and increased mean survival time (27.1±2.8 ver-
sus 35.3±2.8 days, Pb0.05).
Because of the shift of the survival curve, we speculated that in the
absence of DENV1-E106 MAb pressure, within a few days, T329A
DENV-1 might revert to the more virulent A329T parent virus. To
evaluate this, we repeated the intraperitoneal challenge experiments
with the wild type and T329A DENV-1 in the presence of 500 μg of
DENV1-E106 that was administered one day prior to infection. As an-
ticipated, the wild type DENV-1 showed no virulence in the presence
of DENV1-E106 MAb. However, and somewhat unexpectedly, the
T329A DENV-1 variant also showed no virulence when DENV1-E106
MAb was administered (Fig. 3D), suggesting that either reversion of
the escape virus occurred (and this revertant was blocked by
DENV1-E106) or that the low-level of neutralizing activity of the
DENV1-E106 MAb against the T329A virus (EC50 of 7860 ng/ml, see
Fig. 1A) was sufﬁcient to limit virulence in this model. To address
this, we recovered infectious virus from the brains of moribund
mice infected with T329A DENV-1 and obtained viral RNA sequences
directly after RT-PCR ampliﬁcation of viral RNA of brain homogenates
or after plaque puriﬁcation. Remarkably, all viral RNA sequences
retained the T329A mutation in the E protein, with no other speciﬁc
changes in the E protein identiﬁed. Consistent with this, 12 indepen-
dent plaque-puriﬁed viruses from brain homogenates retained resis-
tance to DENV1-E106 by plaque reduction neutralization assay
(data not shown). Thus, although the T329A virus was attenuated
and relatively resistant to DENV1-E106 MAb in mice, in vivo reversion
did not occur frequently and DENV1-E106 MAb could still inhibit the
virulence of the escape virus.tracranial route with (A) 101, (B) 102, or (C) 103 PFU of wild type or T329AWest-Pac-74
er group. No differences were statistically signiﬁcant. D. AG129 mice were untreated or
-74 DENV-1. The number of animals for each antibody ranged from 10 to 18 per group.
Table 2
Virus mutations isolated from in vivo passage in AG129 mice.
Wild type virus, No MAb T329A virus, No MAb Wild type virus DENV1-E106 MAb
K90R (prM) 0/8a (0)b 0/8 (0) 22/24 (92)
V83L (Envelope) 0/8 (0) 0/8 (0) 23/24 (96)
E202K (Envelope) 4/8 (50) 8/8 (100) 12/24 (50)
T329A (Envelope) 0/8 (0) 8/8 (100) 0/24 (0)
AG129 mice were infected with 105 PFU of wild type DENV-1 West-Pac-74 or T329A mutant virus by an intraperitoneal route. Two days later, some of the mice receiving wild type
viruses were administered a single 500 μg dose of DENV1-E106 by an intraperitoneal route. Brain homogenates were collected from all mice at 21 days and processed for viral RNA
sequencing (see Materials and methods).
a Indicates # isolates with mutation/total # of isolates.
b Indicates the mutation frequency.
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As the T329A DENV-1 cell culture derived escape variant retained
sensitivity to DENV1-E106 MAb in vivo, we subsequently assessed
the potential for emergence of resistant variants directly by recover-
ing viruses from mice infected with wild type virus during MAb
treatment. Ten AG129 mice were infected with 105 PFU of wild
type DENV-1 West-Pac-74 and treated with a single 500 μg dose of
DENV1-E106 MAb on day two post-infection. Whereas 8 of 10
mice showed complete protection with no evidence of clinical dis-
ease, two mice developed signs of infection by day 21 including leth-
argy and weight loss. Brain homogenates were recovered from these
animals as well as control mice infected with wild type or T329A
mutant DENV-1 West-Pac-74 in the absence of DENV1-E106 treat-
ment. Viral RNA was obtained from plaque picks from brain homog-
enates corresponding to the mice receiving wild type virus
+DENV1-E106 MAb, or receiving wild type or T329A mutant virus
without MAb treatment, and the structural genes were sequenced
in their entirety (Table 2). Notably, none of the plaque isolates
from DENV1-E106-treated ill mice contained the T329A escape mu-
tation. Instead, 22 of the 24 plaque picks isolated from mice receiv-
ing DENV1-E106 treatment had viral RNA sequences containing
conservative mutations in prM (K90R) and DII of the E protein
(V83L); despite the presence of these mutations, bulk brain tissue
homogenates and all plaque isolates remained sensitive to neutrali-
zation by DENV1-E106, and substitution of the V83L, K90R, or
V83L+K90R mutations into DENV-1 West-Pac RVP also failed to
confer resistance (Figs. 1G–I). Thus, while treatment failure with
DENV1-E106 MAb was possible and resulted in mutation from the
wild type virus, surprisingly, this was not associated with neutraliza-
tion escape.
Discussion
Antibody-based therapy is currently being explored as a platform
for pre- and/or post-exposure treatment of ﬂavivirus infections
(Diamond, 2009). For DENV in particular, theoretical concerns re-
garding exacerbation of acute disease and increasing the likelihood
of DHF/DSS through the induction of antibody-dependent enhance-
ment of infection (ADE) have been minimized by modiﬁcation of se-
quences in the Fc region to eliminate binding to Fc-γ and complement
receptors (Balsitis et al., 2010; Beltramello et al., 2010). Nonetheless,
for DENV, where humans are an integral part of the natural cycle, the
emergence of resistance and transmission of variants to mosquitoes
could rapidly render costly therapeutic antibodies ineffective. To ex-
plore this question, we evaluated the potential for resistance of our
most potently and broadly neutralizing MAb against DENV-1.
Although selection of neutralization escape variants in cell culture
occurred, we recovered only one mutant (T329A) from 30 different
plaque-puriﬁed viruses in the course of two independent experi-
ments. Resistance can occur via selection of a pre-existing mutant
subpopulation or through the emergence of variant viruses during
prolonged treatment (Margeridon-Thermet and Shafer, 2010).Given that a single mutation with the same nucleotide change was
observed in all independent plaque variants, it seems likely that the
T329A variant existed as a small subpopulation within the original
viral stock. The T329A variant was attenuated in culture in BHK21-
15 mammalian and C6/36 insect cells, with decreased replication in
single- and multi-step growth analyses. Somewhat surprisingly, this
attenuated phenotype was not observed in A. aegypti mosquitoes
after feeding by blood meal; instead, and for reasons that remain
unclear, the T329A variant showed a higher level of infectivity com-
pared to the neutralization sensitive parent strain. We conﬁrmed
that feeding mosquitoes ingested the wild type and T329A mutant
virus equivalently by harvesting tissues immediately after blood
meal, and assaying viral RNA by RT-PCR. A related disparity between
infectivity in C6/36 cells and A. aegypti mosquitoes was recently de-
scribed with DENV-2 engineered with mutations in the adjacent FG
loop (residues 382 to 385) on DIII (Erb et al., 2010); in that study,
however, an opposing phenotype was described, as mutant DENV-2
replicated efﬁciently in insect cells but was compromised in mosqui-
toes fed blood meals or inoculated by intrathoracic injection. The low-
level (in our case, 0%) infectivity rate with DENV-1 West-Pac-74 wild
type virus after oral feeding of a blood meal has been reported previ-
ously in A. aegypti mosquitoes (Whitehead et al., 2003). The virus-
host cell interactions that mediate midgut infection of A. aegypti by
DENV remain poorly understood, and wide variation in infectivity
has been observed among DENV serotypes (Gubler et al., 1979) and
genotypes within a given serotype (Armstrong and Rico-Hesse,
2001, 2003). Since the T329Amutation was selected based on its abil-
ity to escape MAb neutralization and maps to a region of DIII that has
been postulated to participate in virus attachment to host cells
(Bhardwaj et al., 2001; Chu et al., 2005; Lee et al., 2006; Zhang et
al., 2010), this residue could have functional signiﬁcance in mediating
midgut infection of mosquitoes. Although this particular observation
was unexpected, it was reproducible, consistent with known varia-
tion in DENV strain infectivity of mosquitoes, and warrants further
investigation.
The central ﬁnding derived from the mosquito experiments, how-
ever, is that in most insects the T329A mutation was not puriﬁed dur-
ing the extrinsic phase of replication. Analogously, T329A DENV-1
showed no change in virulence after intracranial infection of mice
and only a modest attenuation after intraperitoneal infection, without
evidence of reversion. Thus, and somewhat surprisingly, analysis of
attenuation of variant viruses in cell culture did not directly predict
their behavior in insects or animals. In addition to understanding
the signiﬁcance of cell culture selected escape mutants of therapeutic
antibodies, this ﬁnding may be relevant for characterization of live
ﬂavivirus vaccines that contain attenuating mutations, whose pheno-
type is initially selected based on altered replication in cell culture.
Prior experiments with WNV and the highly therapeutic MAb E16
identiﬁed an escape mutant (K307E) that was completely resistant to
neutralization in vitro even at high MAb concentrations, and this cor-
related with a failure to protect in vivo after passive antibody transfer
and infection with an in vitro-derived escape variant (Zhang et al.,
2009). In comparison, even though the T329A variant was ~500-
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cell culture and could cause lethal infection in AG129 mice in the ab-
sence of antibody without reversion, its pathogenesis still was inhib-
ited when mice were pretreated with DENV1-E106 MAb. Although
further study is warranted, this could reﬂect the residual neutralizing
activity that DENV1-E106 MAb has for DENV-1 T329A (EC50 of ~8 μg/
ml) or an enhanced protection that is conferred by the effector func-
tions of the Fc region of antibodies. We also were unable to select for a
bona ﬁde escape mutation in vivo in the presence of DENV1-E106
MAb, even though treatment failure occurred; these results are anal-
ogous to studies with WNV E16 MAb in which escape mutants in vivo
were not identiﬁed during the acute course of infection; rather sus-
tained treatment over months was required before emergence of an
escape variant was observed (Zhang et al., 2009). Binding of the com-
plement component C1q can reduce the stoichiometric threshold for
antibody-mediated neutralization and improve the potency of anti-
bodies 5 to 20-fold, depending on the isotype (Mehlhop et al.,
2009), and activating Fc-γ receptors can enhance protection against
ﬂaviviruses in vivo (Chung et al., 2006, 2007; Oliphant et al., 2005;
Schlesinger et al., 1993; Vogt et al., 2011) through enhanced phagocy-
tosis or antibody-dependent cellular cytotoxicity. Future testing of
aglycosyl variants of DENV1-E106 MAb that lack the ability to bind
C1q or Fc-γ receptors (Tao and Morrison, 1989) with wild type and
T329A West-Pac-74 viruses will help to deﬁne whether antibody ef-
fector functions explain the residual protective activity in vivo against
the T329A escape variant and the failure to select treatment-resistant
variants.
In summary, whereas a single neutralization escape variant was
selected rapidly in cell culture, distinct phenotypes with this virus
were observed in vivo in mosquitoes andmice. Emergence of resistant
variants could occur with single MAb therapeutics against DENV dur-
ing an epidemic if introduction into the mosquito vector does not pu-
rify the mutation. Alternatively, the use of combinations of
neutralizing MAbs that recognize distinct epitopes could limit the
rapid development of resistance.
Materials and methods
Cells, virus and mice
The Dengue virus type-1 strain (West-Pac-74, genotype 4) was
obtained from Dr. Stephen Whitehead (NIAID, NIH, Bethesda, MD)
and ampliﬁed in C6/36 A. albopictus cells according to previously de-
scribed protocols (Shrestha et al., 2010). BHK21-15 cells were cul-
tured in Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Omega Scientiﬁc) and antibiotics
(penicillin G and streptomycin) at 37 °C in a humidiﬁed 5% CO2 incu-
bator. BHK21-15 cells were used to determine DENV-1 West-Pac-74
stock titer by standard plaque assay (Shrestha et al., 2010).
IFNαβR−/−×IFNγR−/− mice on the 129 Sv background (AG129
mice) were a gift from Dr. Skip Virgin (Washington University School
of Medicine) and bred in a pathogen-free barrier facility. All mouse
studies were carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Insti-
tutional Animal Care and Use Committee at the Washington Universi-
ty School of Medicine (Assurance Number: A3381-01).
Selection of the T329A neutralization escape mutant in cell culture
To select a variant that escaped neutralization by DENV1-E106 MAb,
the genotype 4 DENV-1 strain West-Pac-74 (4×105 PFU) was incubated
with 10 μg/ml of DENV1-E106 for 1 h at room temperature in DMEM
supplemented with 10% FBS. The mixture was added to BHK21-15 cells
in a six-well plate and incubated for 2 h at 37 °C. Wells were washed
three times, fresh DMEM medium containing 10 μg/ml of DENV1-E106MAb was added, and cells were incubated at 37 °C for 96 h. Supernatant
was harvested, mixed with 20 μg/ml of fresh DENV1-E106 mAb, and the
selection process was repeated for two additional passages. After the
third passage under MAb selection, supernatants were titrated for resis-
tant viruses by performing a plaque reduction neutralization test
(PRNT)50 assay in BHK21-15 cells in the presence of DENV1-E106
MAb. After conﬁrmation of an escape phenotype, plaques formed under
DENV1-E106 MAb selection were visualized using a neutral red overlay.
Plaque-puriﬁed virus was recovered, ampliﬁed under MAb selection
(10 μg/ml) in BHK21-15 cells for three days at 37 °C, and supernatants
were stored aliquotted at −80 °C. Infected BHK21-15 cells were trypsi-
nized from wells, washed, and total cellular RNA was isolated using an
RNeasy kit (Qiagen). The E gene was ampliﬁed by reverse-transcription
of the viral RNA and cDNA synthesis using the Superscript III One-Step
RT-PCR System (Invitrogen) with the following DENV-1 forward and
reverse primers: 840F: 5′-TGCCATAGGAACATCCATCA-3′ or 850F: 5′-
ACATCCATCACCCAGAAAGG-3′; 1436F: 5′-TGACCGACTACGGAGCTCTT-
3′; 1655R: 3′-TGCTTCTTTGCATGAGCTGT-5′; 2416R: 3′-TGACAAAAATGC-
CACTTCCA-5′, and 2519R: 3′-CTCTTTGGGGAGTCAGCTTG-5′. Direct
sequencing of the gel-puriﬁed PCR products was compared to the
sequence of the laboratory stock DENV-1 West-Pac-74 strain that was
passaged and plaque-puriﬁed in parallel in the absence of MAb
selection.
In vivo selection of escape mutant
In an attempt to generate a neutralization escape virus in vivo,
AG129 mice were infected with 105 PFU of wild type DENV-1 West-
Pac-74 by an intraperitoneal route. Two days later, mice were admin-
istered a single dose of 500 μg of DENV1-E106 by an intraperitoneal
route and monitored for morbidity for 60 days. Ill-appearing mice
were euthanized, and brain tissues were divided for virus titration
in the presence or absence of DENV1-E106 and extraction of total
RNA. To isolate potential escape mutants, virus from brain homoge-
nates was plaque puriﬁed as described previously (Sukupolvi-Petty
et al., 2010). Viral RNA was extracted from brain tissue by using an
RNeasy mini kit (Qiagen) and sequenced as described above along
with an additional forward primer in the capsid gene: 69F: 5′
AGGGTCGACCGTCTTTCAAT-3′ to obtain complete structural gene se-
quences. Viral RNA was extracted from viral supernatants of plaque-
puriﬁed isolates using the QIAamp Viral RNA kit (Qiagen) and
sequenced.
DENV-1 infectious cDNA clone and mutant generation
The DENV-1 West-Pac-74 infectious cDNA clone pRS424DEN1WP
(Puri et al., 2000; Whitehead et al., 2003) (gift of S. Whitehead, Be-
thesda. MD) was used to create wild type and mutant infectious
DENV-1. The T329A single amino acid substitution was introduced
into pRS424DEN1WP by site directed mutagenesis. Wild type and
mutant plasmids were grown in competent BD1528 bacteria at
room temperature and recovered using standard molecular biology
techniques. Plasmids were linearized, treated with proteinase K,
extracted twice with phenol and chloroform, and precipitated with
ethanol at −20 °C overnight. DNA was used as a template for in
vitro DNA-dependent RNA transcription with the AmpliScribe T7 kit
(Epicenter) with the addition of m7G(5′)ppp(5′)A cap analog (New
England BioLabs). Transcription reactions were run at 37 °C for 5 h
and the reaction was then electroporated (3 pulses at 850 V, 25 μF,
∞Ω) into BHK21-15 cells. Cells were added to a T75 tissue culture
ﬂask in DMEM with 10% FBS and observed for the onset of cytopathic
effects (CPE). Once CPE were observed, virus-containing supernatant
was collected, cellular debris pelleted, and supernatant aliquots fro-
zen at −80 °C. The cells remaining in the T75 ﬂask were harvested
and used as a source of viral RNA to conﬁrm that the desired sequence
was retained.
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DENV-1 reporter virus particles (RVP) are pseudo-infectious vi-
rions produced by genetic complementation of a WNV sub-genomic
replicon with the DENV structural genes in trans. Wild type and mu-
tant (T329A (E gene), K90R (prM gene), and V83L (E gene)) DENV-
1 RVP were generated as described previously (Ansarah-Sobrinho et
al., 2008; Dowd et al., 2011); a plasmid expressing the wild type or
mutant C-prM-E genes of DENV-1 (strains West-Pac-74 or 16007)
was cotransfected into 293T cells with a plasmid encoding a WNV
replicon expressing GFP. The C-prM-E plasmid of DENV-1 West-Pac-
74 or 16007 was mutated using the QuikChange site directed muta-
genesis kit (Stratagene) to introduce amino acid substitutions. Super-
natants containing RVP were harvested 72 h after transfection,
ﬁltered through a 0.2 μm ﬁlter, and stored aliquotted at −80 °C.
RVP were incubated with serial dilutions of MAb under conditions
of antibody excess at 37 °C for 1 h. Subsequently, MAb-RVP mixtures
were added to Raji-DCSIGNR cells, which stably express the DC-
SIGNR attachment factor (Davis et al., 2006), and were incubated at
37 °C for 48 h. Infected cells were assayed for GFP expression using
a FACSCalibur ﬂow cytometer (Becton Dickinson).
Phenotype of neutralization escape mutant viruses
Cell culture
The neutralizing activity of DENV1-E106 was determined by using
a plaque reduction neutralization test in BHK21-15 cells as described
previously (Shrestha et al., 2010). Additionally, single- and multi-step
growth curve analysis was performed in BHK21-15 or C6/36 cells
with wild type and mutant DENV-1 at different MOI (5, 1, 0.1, 0.01,
or 0.001) in the presence or absence of 25 μg/ml DENV1-E106 MAb.
Two hours later, free virus was removed and cells were grown in
the presence or absence of 25 μg/ml DENV1-E106 MAb at 37 °C.
Two days later, supernatants were harvested, and virus production
was determined by plaque assay in BHK21-15 cells.
Mice
To determine the virulence of T329A escape viruses, AG129 mice
were infected with wild type or mutant virus at 101, 102 or 103 PFU
by intracranial infection or 105 PFU by intraperitoneal infection.
Mice were monitored for morbidity and mortality for 60 days. Brain
tissues were harvested when mice were moribund and stored at
−80 °C. To assess whether DENV1-E106 MAb could protect mice
after infection with the T329A escape virus, AG129 mice were admin-
istered single dose of 500 μg/mouse antibody one day before intra-
peritoneal infection with 105 PFU of wild type and mutant virus.
Mosquito infection
A. aegyptimosquitoes (Rexville D strain) were provided by Dr. Ken
Olson (Colorado State University) and reared according to standard
procedures. Adult females were fed a mixture of deﬁbrinated goose
blood and either wild type or T329A DENV-1 in a 1:1 blood:virus
ratio. ATP was added to the bloodmeal at a ﬁnal concentration of
2 mM. Undiluted titers of the wild type and mutant viruses were
3.1×106 PFU/ml and 2.6×106 PFU/ml, respectively. After feeding,
mosquitoes were anesthetized, and engorged females separated into
cartons and held for a 14-day extrinsic incubation period (EIP) at
28 °C, 70 to 80% relative humidity, and a 16:8 photoperiod. In sepa-
rate experiments, mosquitoes were fed a blood meal using the same
virus stocks, and harvested within 1 h of feeding.
Viral RNA sequencing from mosquitoes
Whole mosquito bodies were collected, homogenized in RLT lysis
buffer, and RNA was extracted using RNeasy kits (Qiagen, ValenciaCA). Samples were screened for DENV-1 infection using a OneStep
RT-PCR Kit (Qiagen, Valencia CA) and primers that ampliﬁed a 500
nucleotide region in domain III of the envelope (E) gene (1546F: 5′-
ATCATGGCTCGTCCACAAAC-3′ and 2045R: 5′-GCTCCGCTTCAATGTT-
GACT-3′). This region contains the single nucleotide polymorphism
that differentiates the wild type and mutant viruses. RT-PCR reactions
from positive mosquitoes were puriﬁed using either QIAquick PCR
puriﬁcation kits (Qiagen, Valencia CA) or StrataPrep PCR puriﬁcation
kits (Stratagene, La Jolla CA). Amplicons were sequenced using a
primer annealing 149 bases upstream (1771F: 5′-TGCAGGACACCT-
GAAATGCAG-3′) of the single nucleotide polymorphism (Genewiz,
South Plainsﬁeld NJ). Sequence chromatograms were analyzed to as-
sess reversion to the wild type sequence using the PERL script
PolySNP (Hall and Little, 2007).
Statistical analysis
All data were analyzed using Prism software (GraphPad software).
For survival analysis, Kaplan–Meier survival curves were analyzed by
log-rank test. For growth kinetics and neutralizing titers an unpaired
T-test or analysis of variance was used to determine signiﬁcance.
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